Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
(B cell acute lymphoblastic leukemia lymphoblastic lymphoma)
2,205 results
  • Enrichment of Heterozygous Germline RECQL4 Loss-of-Function Variants in Pediatric Osteosarcoma. [Journal Article]
    Cold Spring Harb Mol Case Stud 2019Maciaszek JL, Oak N, … Kesserwan CA
  • Patients harboring germline pathogenic bi-allelic variants in genes involved in the recognition and repair of DNA damage are known to have a substantially increased cancer risk. Emerging evidence suggests that individuals harboring heterozygous variants in these same genes may also be at heightened, albeit lesser, risk for cancer. Herein, we sought to determine whether heterozygous variants in RE…
  • Blinatumomab: a novel therapy for the treatment of non-Hodgkin's lymphoma. [Journal Article]
    Expert Rev Hematol 2019; :1-10Bukhari A, Lee ST
  • Introduction: Blinatumomab, a first-in-class bispecific T cell engager, is a member of a novel class of bispecific antibody constructs with dual binding specificities. While its primary clinical use has been in B cell acute lymphoblastic leukemia, its role in the treatment of B cell non-Hodgkin's Lymphoma (NHL) is less well established. Areas covered: Herein, the authors provide a brief overview …
  • CD123 as a Therapeutic Target in the Treatment of Hematological Malignancies. [Review]
    Cancers (Basel) 2019; 11(9)Testa U, Pelosi E, Castelli G
  • The interleukin-3 receptor alpha chain (IL-3R), more commonly referred to as CD123, is widely overexpressed in various hematological malignancies, including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia, hairy cell leukemia, Hodgkin lymphoma and particularly, blastic plasmacytoid dendritic neoplasm (BPDCN). Importantly, CD123 is expressed at both the level of leukemic stem cel…
  • Heterogeneity of childhood acute leukemia with mature B-cell immunophenotype. [Journal Article]
    J Cancer Res Clin Oncol 2019Demina I, Zerkalenkova E, … Popov AM
  • CONCLUSIONS: In conclusion, our study shows that BIV subtype is heterogeneous group of leukemia including not only the BL, but also BCP-ALL. In ambiguous cases, only a combination of multiple immunophenotypic, cytomorphologic, and genetic diagnostic technologies can allow the precise discrimination of BL and BCP-ALL and selection of the appropriate treatment scheme.
  • PDQ Cancer Information Summaries: Childhood Non-Hodgkin Lymphoma Treatment (PDQ®): Patient Version [BOOK]
    National Cancer Institute (US): Bethesda (MD) PDQ Pediatric Treatment Editorial Board BOOK
  • This PDQ cancer information summary has current information about the treatment of childhood non-Hodgkin lymphoma. It is meant to inform and help patients, families, and caregivers. It does not give formal guidelines or recommendations for making decisions about health care. Editorial Boards write the PDQ cancer information summaries and keep them up to date. These Boards are made up of experts i…
  • Long-term outcome of patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab. [Journal Article]
    Blood Adv 2019; 3(16):2491-2498Dufner V, Sayehli CM, … Goebeler ME
  • Blinatumomab, the first-in-class CD3/CD19 bispecific T-cell engager antibody construct, has recently been approved for treating patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia. However, the clinical proof of concept of blinatumomab efficacy was initially demonstrated in patients with R/R B-cell non-Hodgkin lymphoma (B-NHL) in the MT103-104 phase 1 dose-escalation an…
New Search Next